GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (XBRU:ARGX) » Definitions » Price-to-Owner-Earnings

argenx SE (XBRU:ARGX) Price-to-Owner-Earnings : (As of Dec. 12, 2024)


View and export this data going back to 2014. Start your Free Trial

What is argenx SE Price-to-Owner-Earnings?

As of today (2024-12-12), argenx SE's share price is €580.20. argenx SE does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for argenx SE's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of argenx SE was 71.84. The lowest was 35.99. And the median was 45.99.


XBRU:ARGX's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 31.745
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-12-12), argenx SE's share price is €580.20. argenx SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €-0.80. Therefore, argenx SE's PE Ratio (TTM) for today is At Loss.

As of today (2024-12-12), argenx SE's share price is €580.20. argenx SE's EPS without NRI for the trailing twelve months (TTM) ended in was €-1.46. Therefore, argenx SE's PE Ratio without NRI for today is At Loss.

During the past 13 years, argenx SE's highest PE Ratio without NRI was 327.41. The lowest was 0.00. And the median was 273.05.


argenx SE Price-to-Owner-Earnings Historical Data

The historical data trend for argenx SE's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Price-to-Owner-Earnings Chart

argenx SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50.17 - - - -

argenx SE Quarterly Data
Jun19 Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of argenx SE's Price-to-Owner-Earnings

For the Biotechnology subindustry, argenx SE's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


argenx SE's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, argenx SE's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where argenx SE's Price-to-Owner-Earnings falls into.



argenx SE Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

argenx SE's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=580.20/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


argenx SE  (XBRU:ARGX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


argenx SE Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of argenx SE's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


argenx SE Business Description

Address
Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.